[
  {
    "ts": "2026-01-07T12:48:23+00:00",
    "headline": "Merck Begins Phase 3 Trial of Calderasib With Keytruda QLEX in Non-Small Cell Lung Cancer",
    "summary": "Merck (MRK) said Wednesday it has initiated a phase 3 clinical trial to evaluate calderasib combined",
    "url": "https://finance.yahoo.com/news/merck-begins-phase-3-trial-124823216.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "15004991-c4ba-3059-bae4-831ea3a4ff23",
      "content": {
        "id": "15004991-c4ba-3059-bae4-831ea3a4ff23",
        "contentType": "STORY",
        "title": "Merck Begins Phase 3 Trial of Calderasib With Keytruda QLEX in Non-Small Cell Lung Cancer",
        "description": "",
        "summary": "Merck (MRK) said Wednesday it has initiated a phase 3 clinical trial to evaluate calderasib combined",
        "pubDate": "2026-01-07T12:48:23Z",
        "displayTime": "2026-01-07T12:48:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-begins-phase-3-trial-124823216.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-begins-phase-3-trial-124823216.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T11:50:00+00:00",
    "headline": "Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC",
    "summary": "RAHWAY, N.J., January 07, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluating calderasib (MK-1084), an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of patients with KRAS G12C-mutant, advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).",
    "url": "https://finance.yahoo.com/news/merck-initiates-phase-3-kandlelit-115000422.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "b532d15e-bc48-331b-a970-e9c8ca83f074",
      "content": {
        "id": "b532d15e-bc48-331b-a970-e9c8ca83f074",
        "contentType": "STORY",
        "title": "Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC",
        "description": "",
        "summary": "RAHWAY, N.J., January 07, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluating calderasib (MK-1084), an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of patients with KRAS G12C-mutant, advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).",
        "pubDate": "2026-01-07T11:50:00Z",
        "displayTime": "2026-01-07T11:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/17aa6c5d82094f902222cb82a9850432",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0hcRKnAvle_1UGXmzCIB3Q--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/17aa6c5d82094f902222cb82a9850432.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7ndZCJRGLrHJn5Vh0EMawg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/17aa6c5d82094f902222cb82a9850432.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-initiates-phase-3-kandlelit-115000422.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-initiates-phase-3-kandlelit-115000422.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T11:45:00+00:00",
    "headline": "Merck to Complete Acquisition of Cidara Therapeutics",
    "summary": "RAHWAY, N.J., January 07, 2026--Merck to Complete Acquisition of Cidara Therapeutics",
    "url": "https://finance.yahoo.com/news/merck-complete-acquisition-cidara-therapeutics-114500819.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "8fb794a8-36b0-3311-bc24-76f847d0e428",
      "content": {
        "id": "8fb794a8-36b0-3311-bc24-76f847d0e428",
        "contentType": "STORY",
        "title": "Merck to Complete Acquisition of Cidara Therapeutics",
        "description": "",
        "summary": "RAHWAY, N.J., January 07, 2026--Merck to Complete Acquisition of Cidara Therapeutics",
        "pubDate": "2026-01-07T11:45:00Z",
        "displayTime": "2026-01-07T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/bcf4baf8584f1d548ba01176a4b5786a",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hyeFI2lrYDdgM.6Tm5YIHw--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bcf4baf8584f1d548ba01176a4b5786a.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sCLlrDUqCc56U.PHk4_1NA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bcf4baf8584f1d548ba01176a4b5786a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-complete-acquisition-cidara-therapeutics-114500819.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-complete-acquisition-cidara-therapeutics-114500819.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CDTX"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T11:30:00+00:00",
    "headline": "Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3",
    "summary": "RAHWAY, N.J., January 07, 2026--Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3",
    "url": "https://finance.yahoo.com/news/merck-hold-fourth-quarter-full-113000481.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "ba615939-0a9f-32c9-98f1-e2107fa2de6e",
      "content": {
        "id": "ba615939-0a9f-32c9-98f1-e2107fa2de6e",
        "contentType": "STORY",
        "title": "Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3",
        "description": "",
        "summary": "RAHWAY, N.J., January 07, 2026--Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3",
        "pubDate": "2026-01-07T11:30:00Z",
        "displayTime": "2026-01-07T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/f9d602a92c904f1c427cc2d95fd9e343",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l9IrnS_NXYg3IDvtq8rP3Q--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f9d602a92c904f1c427cc2d95fd9e343.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/of7TiqCVpapzxsoTyQr4ow--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f9d602a92c904f1c427cc2d95fd9e343.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-hold-fourth-quarter-full-113000481.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-hold-fourth-quarter-full-113000481.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]